

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Previously Presented) A composition for topical or transdermal administration consisting essentially of: (i) nicotine, caffeine or hydrocortisone; and (ii) Gilsonite oil, and wherein Gilsonite oil is the major proportion ingredient.
2. - 5. (Canceled)
6. - 36. (Canceled)
37. (Previously Presented) A composition for topical or transdermal administration comprising: (i) nicotine, caffeine or hydrocortisone; and (ii) about 1 to about 80 wt % Gilsonite oil having a viscosity of about 5 to 1,000 cps at 25°C, and a specific gravity of about 0.8 to 0.95.
38. (Previously Presented) The composition of claim 37, wherein the Gilsonite oil has a viscosity of about 5 to 100 cps.
39. (Previously Presented) The composition of claim 37, wherein the Gilsonite oil is about 2 to about 50 wt % of the composition.
40. (Previously Presented) The composition of claim 37, wherein the composition further comprises pharmaceutically acceptable additives selected from the group consisting of excipients, preservatives, antioxidants, fragrances, emulsifiers, dyes, adhesives, polymers, and additional penetration enhancers.
41. (Previously Presented) A composition for topical or transdermal administration consisting of: (i) nicotine, caffeine or hydrocortisone; and (ii) Gilsonite

oil.

42-43. (Canceled).

44. (New) A composition for topical or transdermal administration comprising: (i) caffeine or hydrocortisone; and (ii) at least about 50% by weight Gilsonite oil, wherein the composition is effective achieving 17.66 µg/cm²/hr skin penetration of the caffeine or 0.1862 µg/cm²/hr skin penetration of the hydrocortisone.